Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

Results were announced from a trial evaluating durvalumab with FLOT chemo as perioperative treatment for resectable early stage gastric/GEJ cancers.

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Please note that following on from information provided to NICE by the company in February 2024 the appraisal was suspended from NICE’s work programme. As no further information has been received from ...